期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

西格列汀对2型糖尿病患者血清chemerin水平的影响 被引量：3

下载PDF
导出
摘要 Chemerin是一种新发现的脂肪细胞因子,能够调节脂肪细胞分化,在糖脂代谢中发挥重要作用。研究发现,血清chemerin与肥胖、代谢综合征、糖尿病的发生密切相关。西格列汀属于二肽基肽酶-4（DPP-4）抑制剂,通过选择性抑制DPP-4,减少胰高糖素样肽-1（GLP-1）的降解,延长GLP-1的作用时间,促进胰岛素分泌,降低血糖,改善胰岛功能。本研究旨在观察西格列汀对2型糖尿病（T2DM）患者血清chemerin水平的影响，探讨其在T2DM治疗中的作用机制。
作者 马菁菁 罗跃娥 张捷 高雪
机构地区 天津医学高等专科学校 天津医科大学代谢病医院 天津市医药采购中心
出处 《中国实验诊断学》 2014年第8期1297-1299,共3页 Chinese Journal of Laboratory Diagnosis
关键词 CHEMERIN 2型糖尿病 血清 患者 CHEMERIN 脂肪细胞因子 脂肪细胞分化 胰高糖素样肽
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献12

  • 1Kostopoulos CG, Spiroglou SG, Varakis JN, et al. Chemerin and CMKLR1 expression in human arteries and periadventitial fat: a possible role for local chemerin in atherosclerosis[J]. BMC Card- iovasc Disord,2014,14(1) :56.
  • 2Ye Z, Wang S, Yang Z, et al. Serum lipocalin-2, cathepsin S and chemerin leves and nonalcoholic fatty liver disease[J]. Mol Biol Rep,2014,41(3) :1317.
  • 3Garg SK,Moser EG,Bode BW,et al. Effect of sitagliptin on post prandial glucagon and GLP-1 levels in patients with type 1 diabe- tes, investigator-initiated, double-blind, randomized, placebo con- trolled trial[J]. Endocr Pract,2013,19(1) : 19.
  • 4Morales PE, Torres G, Sotomayor-Flores C, et al. GLP-1 promotes mitochondrial metabolism in vascular smooth muscle cells by en- hancing endoplasmic reticulum-mitochondria coupling [J]. Bio chem Biophys Res Commun,2014,446(1):410.
  • 5Derosa G,Ragonesi PD,Fogari E, et al. Sitagliptin added to previ ously taken antidiabetic agents on insulin resistance and lipid pro- file: a 2 year study evaluation[J]. Fundam Clin Pharmacol, 2014, 28(2) ,221.
  • 6Garg K, Tripathi CD, Kumar S. Clinical review of sitagliptin: a DPP-4 inhibitor[J]. J Assoe Physicians India,2013,61(9):645.
  • 7Yanai H, Adachi H, Hamasaki H, et al. Effects of 6-month sita- gliptin treatment on glucose and lipid metabolism,blood pressure, body weight and renal function in type 2 diabetic patients:a chart- based analysis[J]. J Clin Med Res, 2012,4 (4), 251.
  • 8Koren S,Shemesh Bar L,Tirosh A,et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients[J]. Diabetes Technol Ther, 2012,14(7) : 561.
  • 9Ogawa S, Ishiki M, Nako K, et al. Sitagliptin, a dipeptidyl pepti dase-4 inhibitor,decreases systolic blood pressure in Japanese hy- pertensive patients with type 2 diabetes[J]. Tohoku J Exp Med, 2011,223(2) :133.
  • 10Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on gly- cemic control,13-cell function and insulin resistance in type 2 dia- betic patients[J]. Diabetes Res Clin Pract,2012,98(1) :51.

同被引文献26

  • 1ZHOU Z G,XIANG Y F,JI L,et al.Frequency,immunogenetics,and clinical characteristics of latent autoimmune diabetes in China(LADA China study)a nationwide,multicenter,Clinic-Based Cross-Sectional study[J].Diabetes,2013,62(2):543-550.
  • 2ANDERSEN C D,BENNET L,NYSTROM L,et al.Worse glycaemic control in LADA patients than in those with type 2 diabetes,despite a longer time on insulin therapy[J].Diabetologia,2013,56(2):252-258.
  • 3MI H W,KOLB H,SCHLOOT N,et al.Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype:Action LADA 7[J].Diabetes Care,2013,36(4):908-913.
  • 4ZAMPETTI S,CAPIZZI M,SPOLETINI M A,et al.GADA Titer-Related risk for Organ-Specific autoimmunity in LADA subjects subdivided according to gender(NIRAD study 6)[J].Journal of Clinical Endocrinology&Metabolism,2012,97(10):3759-3765.
  • 5SHIRAKAWA J,FUJII H,OHNUMA K,et al.Diet-Induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice[J].Diabetes,2011,60(4):1246-1257.
  • 6VENKATASAMY V V,PERICHERLA S,MANTHURUTHIL S,et al.Effect of physical activity on insulin resistance,inflammation and oxidative stress in diabetes mellitus[J].J Clin Diagn Res,2013,7(8):1764-1766.
  • 7DURSUN A,CICEK S,KENI F M,et al.The relation of PONl-L55M gene polymorphism and clinical manifestation of Behcet's disease[J].Acta Biochim Pol,2014,61(2):271-274.
  • 8LEE M,RHEE M K.Sitagliptin for type 2 diabetes:a 2015 update[J].Expert Rev Cardiovasc Ther,2015,13(6):597-610.
  • 9HIRAKAWA H,ZEMPO H,OGAWA M,et al.A DPP4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice[J].PLoS One,2015,10(3):e0119360.
  • 10王凯亮,韩旸,李洪梅.DPP-Ⅳ抑制剂西格列汀的作用机制及临床应用[J].中华临床医师杂志（电子版）,2012,6(17):5209-5211. 被引量：14

引证文献3

二级引证文献8

中国实验诊断学
2014年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部